The expression of poly‐(GP) peptides in CSF from C9+ve ALS patients and cell lines has recently emerged as a potential pharmacodynamic and target engagement biomarker in C9+ve ALS patients.16 The gene discussed is C9; the disease is amyotrophic lateral sclerosis.